RNA vax for RSV

"Vaccine efficacy was 83.7% (95.88% confidence interval [CI], 66.0 to 92.2) against RSV-associated lower respiratory tract disease with at least two signs or symptoms and 82.4% (96.36% CI, 34.8 to 95.3) against the disease with at least three signs or symptoms."

https://www.nejm.org/doi/full/10.1056/NEJMoa2307079?query=featured_home